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AUC-guided dosing of tacrolimus prevents progressive systemic
overexposure in renal transplant recipients.
Background. Tacrolimus has a narrow therapeutic window,
and bioavailability is known to vary considerably between renal
transplant recipients. Most centers still rely on measurement of
trough levels, but there are conflicting reports on the correla-
tion between tacrolimus trough levels and systemic exposure, as
measured by the area-under-the-concentration-over-time curve
(AUC(0−12h)).
Methods. We developed and validated a two-compartmental
population-based pharmacokinetic model with Bayesian es-
timation of tacrolimus systemic exposure. Subsequently, we
used this model to apply prospectively AUC-guided dosing of
tacrolimus in 15 consecutive renal transplant recipients. The
main objective was to study intrapatient variability in the course
of time.
Results. Bayesian forecasting with a two-point sampling strat-
egy, a trough level, and a second sample obtained between two
and four hours post-dose significantly improved the squared
correlation with the AUC(0−12h) (r2 = 0.94). Compared with
trough level monitoring only, this approach reduced the 95%-
prediction interval by 50%. The Bayesian approach proved to
be feasible in clinical practice, and provided accurate informa-
tion about systemic tacrolimus exposure in individual patients.
In the AUC-guided dosing cohort the apparent clearance of
tacrolimus decreased gradually over time, which was not re-
flected in corresponding trough levels.
Conclusion. This simple, flexible method provides the op-
portunity to tailor immunosuppression, and should help min-
imize tacrolimus-related toxicity, such as nephrotoxicity and
post-transplant diabetes mellitus.
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The currently available calcineurin inhibitors cy-
closporine microemulsion and tacrolimus both have a
narrow therapeutic window, which makes regular drug
monitoring necessary. Most transplantation centers ad-
just the dose of these drugs to reach or maintain a defined
trough level range. Especially for cyclosporine, several
studies have already documented that estimates of sys-
temic drug exposure, and the absorption profile in par-
ticular, represented by the area-under-the-concentration
over time curve (AUC), correlate better with clinical
events (acute rejections, nephrotoxicity) as compared
with trough levels [1–3]. Prospective studies in de novo
renal transplant recipients have shown that targeting cer-
tain predefined cyclosporine AUC(0−4h) or C2 levels was
associated with a very low incidence of acute rejection
episodes [4, 5].
For tacrolimus, most centers still rely on trough level
monitoring, but there are conflicting data about the cor-
relation with systemic exposure. Some studies reported
a reasonable squared correlation coefficient between
trough levels and tacrolimus AUC(0−12h) (r2 0.60 to 0.85)
[6–8], others found poor correlations (r2 < 0.50) [9, 10].
The observed differences may originate from at least
three factors, including differences in sample sizes, type
of correlation tests used, and time interval after trans-
plantation, at which the studies were done.
In general, a considerable variation in AUC(0−12h) can
be expected in relation to a single trough level, which
of course, is augmented by the range of trough levels
that is thought to be acceptable in clinical practice (e.g.,
tacrolimus trough levels between 10–20 ng/mL early post-
transplant and 5–10 ng/mL in stable transplant recipi-
ents). Similar to cyclosporine, patients with low systemic
tacrolimus exposure in relationship to tacrolimus trough
levels could be expected to have an increased risk of de-
veloping acute or chronic rejection, whereas patients with
a high AUC/C0 ratio are likely to be overdosed.
Prevention of tacrolimus overexposure by AUC
monitoring may be relevant to reduce nephrotoxicity,
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hypertension, and hypercholesterolemia, but the impact
of controlled systemic exposure on these side effects
has not been studied. The increased risk for tacrolimus-
treated patients to develop post-transplant diabetes mel-
litus [11] and polyoma-virus–associated nephropathy
[12], in comparison with cyclosporine treated patients,
may theoretically be reduced by AUC monitoring. Before
the impact of tacrolimus drug exposure can be studied
over longer periods of time, a simple and flexible strat-
egy is needed to estimate systemic drug exposure, since
“full” 12-hour AUC sampling is not a realistic option in
daily practice. The major disadvantage of limiting sam-
pling models with a mathematically derived equation [9]
is the imperative of accurate timing of the blood samples.
When a sample is taken 15 minutes too late, the mathe-
matic equation is no longer valid [13].
Bayesian forecasting is a therapeutic drug monitor-
ing tool that uses pharmacokinetic parameter estimates
(such as mean population drug clearance and volume
of distribution) along with expected associated variabil-
ity and information about the patient (e.g., body weight,
renal function) to predict drug concentrations achieved
with specific doses [14]. Pharmacokinetic parameters for
each patient become individualized, and the influence
of the population parameters decreases [15]. Optimally,
these techniques also inform the clinician of the next
appropriate dose to maintain or reach the desired drug
concentration. The number of blood collections needed,
and the time to reach the required drug concentra-
tions can be reduced [15–17]. We previously described a
population-based, two-compartmental computer model
for cyclosporine [18] that uses Bayesian forecasting com-
bined with a limited sampling strategy, and now used the
same program to analyze pharmacokinetic data obtained
in tacrolimus-treated renal transplant recipients. After
building and validating a new model for tacrolimus, we
prospectively applied AUC-guided dosing to a cohort of
de novo patients during the first postoperative year. The
main objective was to study intraindividual pharmacoki-
netic changes in this for systemic exposure standardized
cohort, in order to be able to design an optimal phar-
macokinetic monitoring strategy for tacrolimus-treated
renal transplant recipients.
METHODS
Population-based model
Using the kin pop module of the pharmacokinetic
software package MW/Pharm version 3.33 (Mediware,
Groningen, the Netherlands) [16], a population two-
compartment model with a lag-time and first-order
absorption pharmacokinetics was calculated using the
tacrolimus dose and the blood concentration values of
20 tacrolimus curves (blood concentration at t = 0, 1,
2, 3, 4, 6, 8, 12 hours) obtained from 17 renal trans-
Table 1. Tacrolimus pharmacokinetic parameters derived from the
model building set of 20 curves, obtained in 17 renal transplant
recipients
Parameter Mean (SD)
tlag hours Lag time 0.956 (0.161)
F Oral bioavailability 0.23 (fixed)
Ka h−1 Absorption rate constant 0.580 (0.524)
V1 L/kg Apparent volume of distribution of
central compartment
0.180 (0.063)
Kelm h−1 Elimination rate constant 0.517 (0.096)
K12 h−1 Distribution rate constant 2.850 (2.219)
(central to peripheral compartment)
K21 h−1 Distribution rate constant 0.384 (0.410)
(peripheral to central compartment)
Table 2. Characteristics of renal transplant recipients whose
tacrolimus curves (N = 64) were used for validation of the model, and
of patients treated with AUC-guided dosing
Validation AUC-dosing
set (N = 26) set (N = 15)
Mean (range) Mean (range)
Age years 46.9 (20–65) 45.9 (33–65)
% Male 65 80
Renal disease
Hereditary 27% 33%
Glomerulonephritis 31% 27%
Hypertension, nephrosclerosis 19% 20%
Other or unknown 23% 20%
Race
Caucasian 80% 87%
African 8% 13%
Oriental 12% 0%
Body weight kg 78.5 (53–114) 81.5 (70–108)
Procedure
Cadaveric, heart-beating 39% 47%
Cadaveric, non–heart-beating 15% 13%
Living related donation 31% 27%
Living unrelated donation 15% 13%
Delayed graft function NA 20%
(need for dialysis)
Cockroft clearance mL/min 60.4 (12–96) 65.6 (16–95)
at 1 year
plant recipients (6 females, 11 males; mean age 45.4
years, mean body weight 73.1 kg; 30% living donation),
and taken at different time points post-transplantation
(11 curves between 2 and 6 weeks, 9 curves between 6
and 52 weeks post-transplantation). Whole blood con-
centrations (ng/mL) were determined by micro particle
enzyme immunoassay (MEIA; Abbott Laboratories, Ab-
bott Park, IL, USA). The MW/Pharm program uses an
iterative two-stage Bayesian procedure to calculate the
mean and standard deviations of the relevant pharma-
cokinetic parameters, as shown in Table 1.
Validation of the model and different limited
sampling strategies
The population-based model was validated in an-
other cohort of 26 renal transplant recipients. The char-
acteristics of this validation group are summarized in
Table 2. The calculated mean population pharmacoki-
netic parameters were individualized for each of 64 curves
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Fig. 1. Tacrolimus blood concentration time curve according to the
population-based model (continuous line), the measured tacrolimus
blood concentrations at t= 0h, 2h, 3h in a patient (•), and the tacrolimus
blood concentration time curve according to the model after fitting the
population parameters to the measured concentrations (dotted line),
after which the AUC0−12h is calculated by the model.
(blood concentration data points at t = 0, 1, 2, 3, 4, 6, 8
hours), based on the tacrolimus dose and different sam-
pling methods, using the maximum a posteriori (MAP)
Bayesian fitting method. Twenty-two of the curves were
obtained in the early postoperative phase (i.e., within two
weeks after transplantation), 42 curves were obtained
between six weeks and 52 weeks post-transplantation.
For each of the combination of time points, individ-
ualized pharmacokinetic parameters were calculated
with the model, from which the AUC0−12h was derived
(Fig. 1). For comparison, the AUC0−12h of the 64 curves
was also calculated using the equation based strategy as
described by Wong et al [9]: AUC0−12h = 16.2 + 2.4 ×
C2h + 5.9 × C4h. The “standard” or reference AUC0−12h
of the 64 curves was calculated from all tacrolimus blood
concentrations using the trapezoidal method (Kin fit
module; MW/Pharm).
Statistics
The AUCs calculated by the different methods were
compared to the standard AUC by Pearson’s correlation
coefficient. C0h (trough levels), C1h, C2h, C3h were also
correlated to the standard AUC by Pearson’s correlation
coefficient. Predictive performance was investigated by
calculating the prediction precision and bias according to
Sheiner and Beal [19].
AUC-guided dosing
This study was approved by the Medical Ethic Com-
mittee of the Leiden University Medical Center. Fif-
teen consecutive de novo renal transplant recipients were
included, and their characteristics are summarized in
Table 2. These patients were prospectively treated ac-
cording to the following AUC-guided dosing protocol:
tacrolimus (starting dose 0.1 mg/kg) was given in a twice-
daily schedule starting three hours before surgery. In the
first week, target trough levels were 12.5 ng/mL (range
10–15 ng/mL). Tacrolimus “full” AUC0−12h was deter-
mined at weeks 2, 6, 12, 26, and 52 using the pharmacoki-
netic model. Limited sampling estimates of AUC0−12h
were obtained at weeks 4, 8, 10, 17, 21, and 39. After each
AUC-assessment dose adjustments were made to reach
the predefined target AUC0−12h: 210 ng.h/mL within the
first six weeks (corresponding with a trough level of 12.5
ng/mL, derived from the model using mean population-
based PK parameters), and 125 ng.h/mL thereafter (cor-
responding with a trough level of 7.5 ng/mL). Because
according to the model there was a linear correlation be-
tween dose and AUC, dose adjustments were made by
the model according to the formula Dnew = Dcurrent ×
AUCtarget/AUCcurrent. Concomitant immunosuppressive
medication consisted of prednisolone (100 mg day 1–3,
50 mg day 4, 20 mg day 5–14, 15 mg day 15–21, 10 mg
after day 22), mycophenolate mofetil, 500 mg b.i.d., and
basiliximab prophylaxis, 20 mg on days 0 and 4. Drugs
that are known to alter concentrations of tacrolimus were
prohibited.
Statistics
Mean pharmacokinetic variables (±SD) resulting from
this strategy [Ctrough (AUC/dose), Tmax, Cmax] were cal-
culated from data obtained at time points of full 0- to
12-hour AUC sampling (t = 2, 6, 12, 26, and 52-week
post-transplantation) and analyzed by repeated measure-
ments analysis of variance (ANOVA) (SPSS, version 11.0,
Chicago, IL, USA).
RESULTS
AUC monitoring
The relationship between tacrolimus trough levels and
standard AUC(0−12h), as calculated by trapezoidal rule,
is plotted in Figure 2A. We found a squared correlation
coefficient of 0.79, which was comparable with previous
studies [6–8]. As a single sample strategy, the three-hour
postdose tacrolimus level had an improved correlation
(r2 = 0.88) with the standard AUC, but still a wide
range of the 95% prediction interval, as is illustrated
in Figure 2B, indicating that the precision is not opti-
mal. The correlation between the Bayesian estimates of
AUC(0−12h) using the tacrolimus concentrations at 0 and
3 hours and the standard AUC(0−12h) was significantly
better (r2 = 0.96, Fig. 2C). This strategy resulted in a
markedly improved precision for an individual measure-
ment. The squared correlation coefficients, bias, and pre-
cision of all the strategies tested to estimate systemic
exposure compared with the standard AUC(0−12h) as de-
termined by trapezoidal rule are summarized in Table
3. All two-point strategies including a trough level with
either a two-, three-, or four-hour sample had a strong
correlation with the standard AUC (r2 = 0.94, 0.96, and
0.95, respectively). Introduction of more samples further
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Fig. 2. Relationship between either (A) predose level (Ctrough, ng/mL), (B) a single sample at 3 hours postdose (C3h, ng/mL), or (C) Bayesian
estimates of AUC0−12h using blood concentrations at 0 and 3 hours postdose (AUC 0h +3h, ng.h/mL) and the AUC0−12h calculated by trapezoidal
rule. The inner lines (– · –) demonstrate the 95% confidence interval, the outer lines the 95% prediction interval.
improved the estimation of systemic exposure. The per-
formance of the limited sampling model, as described by
Wong, was comparable (r2 = 0.92), but the imperative of
exact timing to draw samples at two and four hours post-
dose make this approach inflexible and less attractive for
daily practice. When only the curves obtained two weeks
after transplantation were evaluated, the correlation of
trough levels with the standard AUC was even worse
(r2 = 0.67). In contrast, the correlations of Bayesian esti-
mates derived from all limited sampling procedures were
hardly affected (Table 3). This underlines not only the
large interpatient variability especially in the early post-
transplant period, but also the robustness of the model.
AUC-guided dosing
A total of 15 consecutive de novo renal transplant re-
cipients received tacrolimus-based immunosuppression,
and were prospectively dosed using the described model
and predefined AUC targets. Cumulative incidence of
biopsy proven acute rejection at one year was 6.6% (1
of 15 patients). The only acute rejection episode we en-
countered occurred at day four post-transplantation in a
living, unrelated donation procedure, and could not be
attributed to a low tacrolimus AUC. Patient and graft
survival at one year both were 100%. At one year post-
transplantation, mean GFR, as calculated by the Cock-
roft formula, was 66 mL/min (SD ± 21), mean total
cholesterol 5.3 mmol/L (SD ± 1.3, 32% of patients used
statins), mean systolic blood pressure 139 mm Hg (SD ±
16), mean diastolic blood pressure 82 mm Hg (SD ± 9),
mean number of antihypertensive drugs per patient 1.6
(SD ± 1.0). In Figure 3, for every time point (weeks)
at which tacrolimus AUC was estimated, both the mean
actual AUCs (± SD) and dose corrections (mg/12 hrs)
needed to reach the predefined AUC targets (dotted
Table 3. Pearson correlation coefficients (r2), mean prediction error
(MPE), and mean absolute prediction error (MAPE) of different
strategies to estimate systemic exposure compared with AUC0−12h
determined by trapezoidal rule, based on 64 curves of 26 renal
transplant recipients treated with tacrolimus
r2 <2 wks r2 >2 wks
Sampling r2 MPE MAPE post Tx post Tx
strategy (All curves) (%) (%) (22 curves) (42 curves)
0h 0.79 −3.0 13.4 0.67 0.78
1h 0.48 −7.6 21.2 0.77 0.36
2h 0.77 −3.4 13.3 0.86 0.74
3h 0.88 −1.3 9.5 0.82 0.91
0, 2ha 0.94 1.4 7.6 0.93 0.95
0, 3ha 0.96 0.3 7.1 0.97 0.96
0, 4ha 0.95 −1.3 6.7 0.94 0.96
0, 2, 3ha 0.96 0.8 6.4 0.96 0.97
0, 1, 3ha 0.97 3.7 6.5 0.97 0.98
0, 2, 4ha 0.97 −1.1 5.2 0.96 0.98
0, 1, 2, 3ha 0.97 2.7 6.0 0.97 0.98
0, 1, 2, 3, 4ha 0.98 1.4 4.8 0.98 0.99
0, 1, 2, 3, 4, 6,
8, 12ha
0.99 −0.4 2.2 0.99 0.99
16.2+2.4∗C2h
+5.9∗C4h
0.92 −6.5 8.2 0.96 0.92
aBayesian estimation.
lines) are plotted. It is important to stress that no dose cor-
rections were made in between these time points. There
were no episodes of suspected nephrotoxicity, resulting
in dose reductions. Despite the corrections made at week
two and week four (“early phase”), the standard devia-
tion of tacrolimus AUCs at week four and week six was
considerable. These data indicated that intraindividual
changes in pharmacokinetic parameters are still occur-
ring in this early phase after renal transplantation. Be-
tween week six and 12 by protocol the target AUC was
stepwise reduced to 125 ng.h/mL. The AUCs obtained at
12 weeks and later were defined as the “steady phase,”
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Fig. 3. AUC-guided tacrolimus dosing in de novo kidney transplant re-
cipients. Upper: Mean tacrolimus AUCs (± SD) in ng.h/mL and target
AUC (dotted line) ± 20% (gray dotted lines). Lower: Dose corrections
(± SD and range) in mg, calculated by the model, to reach these tar-
gets. Beyond 6 weeks (according to the protocol), the target AUC was
lowered, which was implemented gradually between 6 and 10 weeks
post-transplantation for safety reasons. For this reason, the dose cor-
rections at these time points are shown in gray.
and showed stabilization of the intrapatient variability.
This was also reflected in a decrease of dose corrections in
the “steady phase” needed to maintain the AUCs within
the target range.
Further analysis of the tacrolimus curves, obtained at
week two and week six, indicated an increase in the AUC
that was predominantly determined by the absorption
phase of the curve (Fig. 4A and B). Not only in the
“early phase,” but also between weeks 12 and 52, there
was a rise in the tacrolimus dose corrected concentra-
tion curves (Fig. 4C and D). The corresponding pharma-
cokinetic variables are summarized in Table 4, showing a
steady and significant increase over time of (AUC/dose),
while this was not reflected in a change of (Ctrough/dose)
in the “stable phase” (P = 0.01, repeated measurements
ANOVA analysis, linear test of within subjects contrast).
DISCUSSION
There is increasing evidence that dosing of cy-
closporine microemulsion, guided by estimation of the
absorption profile of the drug, is superior as com-
pared with trough level monitoring. Adequate systemic
exposure was associated with a reduced incidence of
acute rejection episodes, cyclosporine-related nephrotox-
icity, and cardiovascular risk factors, including hyperten-
sion and hypercholesterolemia. A critical appraisal of
tacrolimus monitoring by trough levels only has thus far
not received much attention, partly because earlier re-
ports suggested that tacrolimus trough levels correlated
better with systemic exposure [8]. Our data indicate that
also in case of maintenance therapy with tacrolimus, a
trough level is not a reliable tool to estimate systemic ex-
posure in renal transplant recipients. Until now, no con-
clusive prospective trials [10, 20]have been published that
evaluated the correlation between tacrolimus exposure
and rejections or side effects. Kuypers et al [21] reported
a tendency for a lower incidence of acute rejection in re-
lationship with simultaneous, adequate AUCs for both
tacrolimus (>150 ng.h/mL) and mycophenolate mofetil
(>45 ng.h/mL) at day seven compared with patients who
did not reach both targets. Although no differences in
AUC were found in patients with versus patients without
hypertension, hyperlipidemia, and nephrotoxicity, they
did report a significant higher AUC in patients with
infectious complications compared to patients without
infections.
Our population-based computer model with Bayesian
fitting improved significantly the estimation precision to
predict the AUC, requiring a trough level in combination
with only one additional, but timed, sample. For illus-
tration: a trough level of 7.5 ng/mL corresponded with
a mean AUC(0−12h) of 135 ng.h/mL, with a 95% predic-
tion interval of 69 to 202 ng/mL. This interval could be
reduced to 108 to 166 ng/mL when a two-point (0 and 3
hours) strategy was followed. By analogy, the 95% pre-
diction interval of a trough level of 12.5 ng/mL could be
improved from an AUC range from 162 to 294 to a range
of 198 to 256 ng.h/mL.
The major advantage of this model is that it can han-
dle sampling at any time point between two and four
hours postdose without influencing its predictive perfor-
mance. This approach is simple and feasible in the outpa-
tient clinic setting. In contrast, limited sampling strategies
based on a mathematical formula become useless when
the obligatory predefined time points are not met. Also,
monitoring guided by a single C2h or C3h level is very
much dependent on accurate timing of the intake of the
drug and the drawing of the samples [13].
We tested our model-based approach prospectively in a
cohort of renal transplant recipients at various time points
in the first postoperative year. Early after transplantation,
there was a change in the absorption phase in at least 50%
of the patients we studied. The performance of the model
combined with two-point sampling, however, was not in-
fluenced by these time-dependent changes in individual
pharmacokinetics. In contrast, the worst correlation of
trough levels with the trapezoidal AUCs was found in the
early period after transplantation (r2 = 0.67). Changes in
absorption or elimination of tacrolimus, resulting in sub-
optimal systemic exposure, are not reliably identified by
trough level monitoring. This is illustrated by the fact that
in our data (validation set and AUC guided dosing set)
only a limited fraction of curves with a trapezoidal AUC
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ng.h/mL) (C, D) in de novo kidney transplant
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Table 4. Mean values of pharmacokinetic variables with time
AUC (0-12h) Ctrough Tmax Cmax Dose tacro Body weight Dose/weight Ctrough/dose AUC/dose
Weeks post Tx ng.h/mL (±SD) ng/mL (±SD) minutes post dose ng/mL mg/12h kg mg/kg conc./mg AUC/mg
(Early phase)
2 weeks 181 (± 50) 11.9 (± 4.7) 130 23.1 6.0 77.5 0.077 2.1 30a
6 weeks 224 (± 67) 13.6 (± 5.5) 121 29.5 6.5 74.8 0.087 2.5 34a
(Steady phase)
12 weeks 129 (± 35) 8.0 (± 2.4) 108 17.5 3.4 74.5 0.046 2.8 38a
26 weeks 139 (± 20) 8.1 (± 2.1) 92 19.1 3.4 76.0 0.044 2.8 42a
52 weeks 130 (± 23) 7.7 (± 1.6) 78 18.5 2.9 76.8 0.038 2.9 45a
aSignificant, P < 0.01 by repeated measures ANOVA analysis.
deviating more than 20% from the target AUCs would
have been detected using trough levels. Using Bayesian
estimates with sampling at zero and three hours post-
dose, this proportion is considerably higher (Table 5). To
narrow the range of accepted trough levels would only
result in a limited improvement of the proportion and,
of course, impair the test specificity. For example, in the
stable period, the sensitivity and specificity of a trough
level >9 ng/mL to predict an AUC >150 ng.h/mL were
0.65, respectively, 0.88 [for comparison: trough level >10
ng/mL: sensitivity 0.50, specificity 0.90; AUC(0h3h) >150
ng.h/mL: sensitivity 0.95, specificity 0.98].
In the first months after transplantation we observed
a considerable standard deviation of the actual reached
AUCs despite dose adjustments. This indicated that early
after transplantation an AUC measurement has a limited
predictive value for drug exposure in the following weeks,
which still makes, in our opinion, frequent monitoring
necessary. After this period only minor dose corrections
were needed to maintain patients within the defined AUC
target range (100–150 ng.h/mL). The difficulty to reach
the target AUC in the first weeks post-transplantation
reflects the changes in intra-individual PK parameters in
this time period. Repeated measurements every three or
four days could help to signalize these changes earlier,
whereas the simplicity of the model facilitates these kinds
of strategies. Also, the system could theoretically be im-
proved by putting the time-related PK changes into the
model. However, the disadvantage of this kind of strate-
gies would be that the simplicity of the model is affected.
In this intensively monitored group of patients with
controlled systemic exposure, the most striking change in
pharmacokinetic parameters was the consistent increase
of dose corrected AUC [(AUC/dose)] of tacrolimus with
time. Since AUC/dose is equal to F/CL, this is a re-
flection of a decrease in apparent clearance, which can
be a result from either an increasing bioavailability, by
improving of absorption, or a decrease in the actual
elimination clearance of tacrolimus over time. Especially
early post-transplantation, the change of the absorption
profiles, as shown in Figure 3, suggests that changing
absorption kinetics in individual patients may be the prin-
cipal cause for this phenomena. Presystemic metabolism
of tacrolimus by the gastrointestinal cytochrome P450
3A (CYP3A) isoenzymes and removal by P-glycoprotein
transport is extensive, and likely to contribute signif-
icantly to large variability in the rate and extent of
drug absorption [22, 23]. CYP3A4 expression is highly
variable between individuals, with up to 30-fold differ-
ences in small intestine expression [24]. Expression of
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Table 5. Relatioship of trough levels and of Bayesian of AUC0−12h using blood concentrations at 0 and 3 hours postdose (AUC 0h3h, ng.h/mL)
with trapezoidal AUCs and their performance as a test to detect “abnormal” exposure of tacrolimus
Early period
(N = 65 curves)
AUC trapezoidal ng.h/mL AUC trapezoidal ng.h/mL
<170 170–250 >250 <170 170–250 >250
Ctrough ng/mL AUC(0h.3h) ng.h/mL
<10 14 8 0 <170 22 2 0
10–15 7 15 4 170–250 1 26 0
>15 2 5 10 >250 0 0 14
Test performance Sens Spec Test performance Sens Spec
High Ctrough > overexposure 0.71 0.86 High AUC(0h3h) > overexposure 1.00 1.00
Low Ctrough > underexposure 0.61 0.81 Low AUC(0h3h) > underexposure 0.96 0.95
Stable period
(n = 72 curves)
AUC trapezoidal ng.h/mL AUC trapezoidal ng.h/mL
<100 100–150 >150 <100 100–150 >150
Ctrough ng/mL AUC(0h3h) ng.h/mL
<5 1 2 0 <100 6 1 0
5–10 7 37 10 100–150 2 42 1
>10 0 5 10 >150 0 1 19
Test performance Sens Spec Test performance Sens Spec
High Ctrough > overexposure 0.50 0.90 High AUC(0h3h) > overexposure 0.95 0.98
Low Ctrough > underexposure 0.13 0.97 Low AUC(0h3h) > underexposure 0.75 0.98
Sens, sensitivity, spec, specificity. Overexposure was defined as a (trapezoidal) AUC0−12h, more than 20% above the target AUC (>250 ng.h/mL, early period; >150
ng.h/mL, stable period), underexposure as an AUC0−12h, more than 20% under target (<170 ng.h/mL, early period; <100 ng.h/mL, stable period).
CYP3A4 in the gut mucosa varies along the intesti-
nal tract, the upper small intestine being the major site
for CYP3A4-mediated first-pass metabolism in humans
[25, 26]. P-glycoprotein lowers intracellular concentra-
tions of tacrolimus by pumping absorbed drug back into
the intestinal lumen. P-glycoprotein may regulate access
of tacrolimus to CYP3A enzymes, preventing these en-
zymes from being overwhelmed by high drug concen-
trations [24]. Tacrolimus is repeatedly transported out
of the intestinal mucosal cells, and then passively reab-
sorbed. At least theoretically, this continuous repeated
exposure could lead to more efficient metabolism [27].
P-glycoprotein shows significant interindividual variabil-
ity, with two- to eight-fold variation found in small in-
testine biopsies from kidney transplant recipients and
healthy volunteers [28]. P-glycoprotein mRNA levels in-
crease longitudinally along the intestine [29]. In addition,
factors such as the poor aqueous solubility of tacrolimus
and alterations in gut motility may cause intraindivid-
ual variability in tacrolimus exposure to CYP450 and P-
glycoprotein systems and, hence, random intraindividual
variability in tacrolimus bioavailibility.
Using trough levels as monitoring tool, this effect
would not have been appreciated since the corresponding
trough levels remained consistently within the generally
accepted target range of 5 to 10 ng/mL. These data sug-
gest that there may be a “silent” and progressive increase
in the systemic exposure in tacrolimus-treated patients,
despite stable trough levels. It is important to note that all
patients in the present study received a standard dose of
10 mg prednisolone beyond day 22 after transplantation.
The observed pharmacokinetic changes can, therefore,
not be attributed to a change in induction of CYP3A as
a result of steroid tapering [30, 31].
CONCLUSION
We present a simple and reliable model-based ap-
proach, which, with only one additive sample, signifi-
cantly improved estimation of tacrolimus exposure. A
trough level in combination with a second sample, ob-
tained somewhere between two and four hours post-
dose, is sufficient to accurately and reliably estimate
tacrolimus AUC, even in the early post-transplant pe-
riod. Especially in the first months (“early phase”) post-
transplantation, this method can serve as a tool to prevent
under- or overexposure compared to trough level mon-
itoring, but changes in intraindividual pharmacokinetics
with time make it necessary to repeat AUC estimations
frequently in this phase. After the first three months,
the intraindividual changes in AUC are minimal, and
in stable outpatients, AUC estimates can be done every
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three months to prevent systemic overexposure with time.
The applicability of AUC-guided tacrolimus dose adjust-
ments can be expanded to overt tacrolimus-associated
complications, such as post-transplant diabetes mellitus,
polyomavirus-associated nephropathy, or unpredictable
changes in tacrolimus exposure in relation to diarrhea
[32]. A prospective study in which AUC-guided dos-
ing is directly compared with trough level monitoring
is the only way to determine the impact on the preven-
tion of acute rejection episodes, nephrotoxicity, and other
known side effects. Once the strategy, to control exposure
over time, is optimized, different target levels of AUC
could be tested in relationship to clinical outcome.
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